Molecular Partners AG
MOLN
Pozycja w akcjach
#19487
Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to... Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. Key among these is Abicipar, a DARPin-based treatment currently in Phase III clinical development for significant ophthalmic conditions like neovascular wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Additionally, their portfolio features multi-specific DARPin candidates targeting infectious diseases, such as MP0420 and MP0423, both designed to combat the SARS-CoV-2 virus (COVID-19). In the oncology space, Molecular Partners is advancing several programs: MP0310, in Phase Ia for immuno-oncology; MP0317, a Phase I tumor-localized immune agonist engineered to activate immune cells within tumors; and MP0274, also in Phase I, aimed at HER2-positive cancers. Further early-stage assets include MP0533, a CD3 T cell candidate for acute myeloid leukemia, and MP0250, which targets vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and human serum albumin (HSA) to enhance therapeutic half-life. The company actively collaborates with leading pharmaceutical companies. Notable alliances include a partnership with Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; agreements with Amgen SA and Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc. They also maintain relationships with various other third-party collaborators. Established in 2004, Molecular Partners AG is headquartered in Schlieren, Switzerland.
Cena akcji
$3.98
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$152.44M
Zmiana (1 dzień)
-1.29%
Zmiana (1 rok)
14.68%
Kraj
CH
Handel Molecular Partners AG (MOLN)
Kategoria
Healthcare
Kapitalizacja rynkowa Molecular Partners AG(MOLN)
Kapitalizacja rynkowa: $152.44M
Na dzień October 2026 spółka Molecular Partners AG ma kapitalizację rynkową wynoszącą $152.44M. Według naszych danych, czyni to Molecular Partners AG 19487th najcenniejszą firmą na świecie pod względem kapitalizacji rynkowej. Kapitalizacja rynkowa to całkowita wartość rynkowa wszystkich wyemitowanych akcji spółki giełdowej i jest powszechnie stosowana do oceny jej wartości.
Historia kapitalizacji rynkowej Molecular Partners AG od 2016 do 2026
MOLN w porównaniu do 5 najpopularniejszych stocks
